Skip to content

To study the clinical efficacy and safety of rush immunotherapy in the treatment of dust mite allergic asthma

To study the clinical efficacy and safety of rush immunotherapy in the treatment of dust mite allergic asthma

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500097682
Enrollment
Unknown
Registered
2025-02-24
Start date
2025-03-01
Completion date
Unknown
Last updated
2025-03-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

allergic asthma

Interventions

experimental group:Subcutaneous rush immunotherapy regimen
normal group:Subcutaneous Conventional immunotherapy

Sponsors

General Hospital of Northern Theater Command of PLA
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: (1) Age: 18-60 years old, meeting the diagnostic criteria of allergic asthma, with or without allergic rhinitis or conjunctivitis; (2) Skin prick test positive for dust mite allergen (>= grade 2); (3) serum dust mite specific ige antibody positive (>= grade 2); (4) patients with stable mild or moderate allergic asthma; (Mild asthma: complete control after stage 1 and stage 2 treatment; Moderate asthma: fully controlled with stage 3 treatment.); (5) Previous history of allergic asthma acute attack; (6) With the consent of the patients, they signed the informed consent and received regular follow-up;

Exclusion criteria

Exclusion criteria: (1) severe uncontrolled asthma (FEV1<70%); (2) with acute or chronic lung diseases, malignant tumors, abnormal heart, liver and kidney, autoimmune diseases, mental disorders, etc.; (3) chronic obstructive pulmonary disease, atelectasis and other respiratory diseases; (4) Patients had poor compliance during follow-up and were not actively cooperative or willing to participate in this study; (5) patients allergic to epinephrine; (6) patients who had received allergen specific immunotherapy or other biological agents.

Design outcomes

Primary

MeasureTime frame
The time of the first attack of allergic asthma after treatment;

Secondary

MeasureTime frame
Percentage of blood eosinophils;Total serum IgE;Serum specific IgE;sIgE/tIgE;skin prick test;Total number of asthma exacerbations in 12 months;Number of use of ventolin;Visual analogue scale (VAS) for asthma and rhinitis;Daily total medication Score (DMS);Asthma Quality of Life questionnaire (AQLQ) score;Asthma Control Test Score (ACT);Lung function;

Countries

China

Contacts

Public ContactChai Ruonan

General Hospital of Northern Theater Command

lily.pad_ff@126.com+86 133 0988 0900

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026